SYS-CON MEDIA Authors: Mat Mathews, PR.com Newswire, David Smith, Tim Crawford, Kevin Benedict

News Feed Item

Favourable Rulings, Topline Results, Earnings Schedules, Approvals, and New Advisory Boards - Analyst Notes on Lilly, UnitedHealth Group, Valeant, Forest Laboratories, and Zoetis

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, April 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Eli Lilly & Co. Analyst Notes 

On March 31, 2014, Eli Lilly & Co. (Lilly) announced that the U.S. District Court for the Southern District of Indiana has ruled in the Company's favor regarding the vitamin dosage regimen patent for Alimta® (pemetrexed for injection). According to the Company, in the case of Eli Lilly and Company v. Teva Parenteral Medicines Inc., et al., the court ruled the vitamin dosage regimen patent is valid and enforceable. Additionally, the Company stated that the patent provides intellectual property protection for Alimta until 2022. Michael J. Harrington, Senior Vice President and General Counsel for Lilly, remarked, "We are pleased with the District Court's ruling on Alimta's vitamin dosage regimen patent and are confident that the patent is valid and enforceable. The significant scientific research that Lilly performed in support of the vitamin dosage regimen patent deserves intellectual property protection. We continue to emphasize that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve." The full analyst notes on Eli Lilly & Co. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/LLY/report.pdf

--

UnitedHealth Group, Inc. Analyst Notes 

On March 27, 2014, UnitedHealth Group, Inc. (UnitedHealth Group) announced that the UnitedHealth Group Center for Nursing Advancement (CFNA) reported the formation of an External Nurse Advisory Board (ENAB). According to UnitedHealth, the goal of the ENAB is to inform, create and evolve nursing best practices in order to create strong partnerships across nursing, education and the health care industry influence nursing policy and changes in the national landscape; and further the nursing profession. Commenting on the development, Jeannine Rivet, Executive Vice President, UnitedHealth Group and Executive Sponsor of the CFNA, stated, "The Center for Nursing Advancement (CFNA) was founded in 2008 to prepare nurses for expanding roles and solving the most pressing health care problems of today and tomorrow, tackling the challenges of a health care system in transition and shaping the future of the health care industry. The ENAB was created to further this mission, not only for the more than 24,000 UnitedHealth Group nurse employees in the United States and seven other countries, but for nurses everywhere." The full analyst notes on UnitedHealth Group, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/UNH/report.pdf

--

Valeant Pharmaceuticals International, Inc. Analyst Notes 

On March 25, 2014, Valeant Pharmaceuticals International, Inc. (Valeant) and Actavis plc (Actavis) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). According to the Company, Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013 and under the terms of the agreement with Valeant, Actavis will acquire the rights to Metronidazole 1.3% for up to $57 million in upfront payments, milestone payments and certain guaranteed royalty payments during the first three years of commercialization depending on market conditions. The Company further stated that Actavis will also pay ongoing royalties to Valeant after the first three years of commercialization. The full analyst notes on Valeant Pharmaceuticals International, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/VRX/report.pdf

--

Forest Laboratories Inc. Analyst Notes 

On March 31, 2014, Forest Laboratories Inc. (Forest Laboratories), together with Gedeon Richter Plc., reported positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression. According to the Company, the trial consisted of four treatment groups: cariprazine 0.75 mg/day, 1.5 mg/day, 3.0 mg/day, and placebo. Commenting on the results, Marco Taglietti, M.D., Executive Vice President of Drug Development and Research at Forest Laboratories, stated, "We are pleased with the positive results of this study. In addition to previously completed Phase III trials in schizophrenia and bipolar mania, we now have positive Phase IIb studies for cariprazine in both bipolar depression and major depressive disorder. Our goal is to continue developing cariprazine for patients with a broad range of psychiatric conditions." The full analyst notes on Forest Laboratories Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/FRX/report.pdf

--

Zoetis Inc. Analyst Notes 

On March 31, 2014, Zoetis Inc. (Zoetis) announced that it will host a webcast and conference call at 8:30 a.m. EDT on May 6, 2014. According to Zoetis, CEO Juan Ramón Alaix and Executive Vice President and CFO Rick Passov will review Q1 2014 financial results and respond to questions from financial analysts during the call. Additionally, the Company stated that a replay of the webcast will be archived and made available on the same day. The full analyst notes on Zoetis Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04112014/ZTS/report.pdf

--


About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsReview.com

 

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.